Structural and molecular basis of the interaction mechanism of selected drugs towards multiple targets of SARS-CoV-2 by molecular docking and dynamic simulation studies- deciphering the scope of repurposed drugs

The repurposing of FDA approved drugs is presently receiving attention for COVID-19 drug discovery. Previous studies revealed the binding potential of several FDA-approved drugs towards specific targets of SARS-CoV-2; however, limited studies are focused on the structural and molecular basis of interaction of these drugs towards multiple targets of SARS-CoV-2. The present study aimed to predict the binding potential of six FDA drugs towards fifteen protein targets of SARS-CoV-2 and propose the structural and molecular basis of the interaction by molecular docking and dynamic simulation. Based on the literature survey, fifteen potential targets of SARS-CoV-2, and six FDA drugs (Chloroquine, Hydroxychloroquine, Favipiravir, Lopinavir, Remdesivir, and Ritonavir) were selected. The binding potential of individual drug towards the selected targets was predicted by molecular docking in comparison with the binding of the same drugs with their usual targets. The stabilities of the best-docked conformations were confirmed by molecular dynamic simulation and energy calculations. Among the selected drugs, Ritonavir and Lopinavir showed better binding towards the prioritized targets with minimum binding energy (kcal/mol), cluster-RMS, number of interacting residues, and stabilizing forces when compared with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, later drugs demonstrated better binding when compared to the binding with their usual targets. Remdesvir showed better binding to the prioritized targets in comparison with the binding of Chloroquine, Favipiravir, and Hydroxychloroquine, but showed lesser binding potential when compared to the interaction between Ritonavir and Lopinavir and the prioritized targets. The structural and molecular basis of interactions suggest that the FDA drugs can be repurposed towards multiple targets of SARS-CoV-2, and the present computational models provide insights on the scope of repurposed drugs against COVID-19.

[1]  Zhènglì Shí,et al.  Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion , 2020, Cell Research.

[2]  Lianyong Liu,et al.  Existing bitter medicines for fighting 2019‐nCoV‐associated infectious diseases , 2020, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[3]  S. Lindstrom,et al.  First Case of 2019 Novel Coronavirus in the United States , 2020, The New England journal of medicine.

[4]  B. Graham,et al.  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation , 2020, Science.

[5]  Nathan A. Baker,et al.  Electrostatics of nanosystems: Application to microtubules and the ribosome , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[6]  P. Cochat,et al.  Et al , 2008, Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.

[7]  Wu Zhong,et al.  Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study , 2020, Engineering.

[8]  Md. Imtaiyaz Hassan,et al.  Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach , 2020, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.

[9]  L. Guddat,et al.  Structure of the RNA-dependent RNA polymerase from COVID-19 virus , 2020, Science.

[10]  Danna Zhou,et al.  d. , 1934, Microbial pathogenesis.

[11]  A. Elfiky,et al.  SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an in silico perspective , 2020, Journal of biomolecular structure & dynamics.

[12]  Peter M. Kasson,et al.  GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit , 2013, Bioinform..

[13]  Bhumi M. Shah,et al.  In silico studies on therapeutic agents for COVID-19: Drug repurposing approach , 2020, Life Sciences.

[14]  Xuhui Huang,et al.  Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro , 2020, Antiviral Research.

[15]  Hydroxychloroquine , 2019, Reactions Weekly.

[16]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[17]  M. Pal,et al.  Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2): An Update , 2020, Cureus.

[18]  E. Pardon,et al.  Influenza A virus RNA polymerase structures provide insights into viral genome replication , 2019, Nature.

[19]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[20]  Tuğba Taşkın Tok,et al.  Using integrated computational approaches to identify safe and rapid treatment for SARS-CoV-2 , 2020, Journal of biomolecular structure & dynamics.

[21]  C. Nelson,et al.  STRUCTURE OF THE SARS-CoV-2 ORF7A ENCODED ACCESSORY PROTEIN , 2020 .

[22]  D. Wang,et al.  The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status , 2020, Military Medical Research.

[23]  E. Castañón,et al.  A Trial of Lopinavir-Ritonavir in Covid-19. , 2020, The New England journal of medicine.

[24]  Tsuyoshi Murata,et al.  {m , 1934, ACML.

[25]  Jianjun Gao,et al.  Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. , 2020, Bioscience trends.

[26]  A. Walls,et al.  Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein , 2020, Cell.

[27]  Y. Zhu,et al.  Structure of the 2019-nCoV HR2 Domain , 2020 .

[28]  gui-qiang Wang,et al.  A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus—A possible reference for coronavirus disease‐19 treatment option , 2020, Journal of medical virology.

[29]  Joe Pardo,et al.  The journey of remdesivir: from Ebola to COVID-19 , 2020, Drugs in context.

[30]  A. Joachimiak,et al.  The crystal structure of papain-like protease of SARS CoV-2 , 2020 .

[31]  R. Hilgenfeld,et al.  Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors , 2020, Science.

[32]  G. Minasov,et al.  2.05 Angstrom Resolution Crystal Structure of C-terminal Dimerization Domain of Nucleocapsid Phosphoprotein from SARS-CoV-2 , 2020 .

[33]  Wu Zhong,et al.  Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro , 2020, Cell Discovery.

[34]  Thanyada Rungrotmongkol,et al.  Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms , 2020, Biochemistry.

[35]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[36]  Lixia Chen,et al.  Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods , 2020, Acta Pharmaceutica Sinica B.

[37]  M. Martínez.  Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus , 2020, Antimicrobial Agents and Chemotherapy.

[38]  F. Buonaguro,et al.  SARS-CoV-2 RNA polymerase as target for antiviral therapy , 2020, Journal of Translational Medicine.

[39]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[40]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[41]  Joy Y. Feng,et al.  Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency , 2020, The Journal of Biological Chemistry.

[42]  Arun K. Ghosh,et al.  GRL-09510, a Unique P2-Crown-Tetrahydrofuranylurethane -Containing HIV-1 Protease Inhibitor, Maintains Its Favorable Antiviral Activity against Highly-Drug-Resistant HIV-1 Variants in vitro , 2017, Scientific Reports.

[43]  P ? ? ? ? ? ? ? % ? ? ? ? , 1991 .

[44]  Science multicenter collaboration group of Department of,et al.  [Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia]. , 2020, Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases.

[45]  E. Abu-Gharbieh,et al.  The Rationale for Potential Pharmacotherapy of COVID-19 , 2020, Pharmaceuticals.

[46]  Xu Liu,et al.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[47]  T. Poulos,et al.  Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir , 2010, Proceedings of the National Academy of Sciences.

[48]  James P. Evans.  The Origin , 2009, Genetics in Medicine.

[49]  O. Glebov.  Understanding SARS‐CoV‐2 endocytosis for COVID‐19 drug repurposing , 2020, The FEBS journal.

[50]  Rajendra Kumar,et al.  g_mmpbsa - A GROMACS Tool for High-Throughput MM-PBSA Calculations , 2014, J. Chem. Inf. Model..

[51]  R. Scheuermann,et al.  A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2 , 2020, Cell Host & Microbe.

[52]  Saurabh Menon,et al.  ACE2 X-Ray Structures Reveal a Large Hinge-bending Motion Important for Inhibitor Binding and Catalysis , 2004, Journal of Biological Chemistry.

[53]  E. Liu,et al.  Company Says It Mapped Part of SARS Virus , 2003 .

[54]  Junmei Wang,et al.  Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study , 2020, Journal of chemical information and modeling.

[56]  W. Kabsch,et al.  X-ray structure of glutathione S-transferase from the malarial parasite Plasmodium falciparum , 2003, Proceedings of the National Academy of Sciences of the United States of America.